State of Wyoming Acquires 11,071 Shares of Illumina, Inc. $ILMN

State of Wyoming increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 137.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,125 shares of the life sciences company’s stock after acquiring an additional 11,071 shares during the quarter. Illumina comprises about 0.3% of State of Wyoming’s investment portfolio, making the stock its 25th biggest holding. State of Wyoming’s holdings in Illumina were worth $2,508,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. JPMorgan Chase & Co. increased its stake in shares of Illumina by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 832,690 shares of the life sciences company’s stock worth $79,081,000 after acquiring an additional 124,246 shares in the last quarter. Elo Mutual Pension Insurance Co bought a new position in shares of Illumina in the 3rd quarter worth about $2,319,000. Caprock Group LLC bought a new position in shares of Illumina in the 3rd quarter worth about $1,479,000. Capital World Investors grew its position in Illumina by 20.0% during the 3rd quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after purchasing an additional 3,331,542 shares during the last quarter. Finally, Nordea Investment Management AB grew its position in Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after purchasing an additional 911,843 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
• Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
• Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
• Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Illumina Stock Performance

Shares of ILMN stock opened at $170.93 on Thursday. Illumina, Inc. has a one year low of $81.75 and a one year high of $172.49. The company’s 50-day moving average is $136.19 and its 200 day moving average is $133.03. The company has a market capitalization of $25.86 billion, a price-to-earnings ratio of 31.08, a price-to-earnings-growth ratio of 2.69 and a beta of 1.50. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently commented on ILMN shares. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup increased their price objective on shares of Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. Royal Bank Of Canada started coverage on shares of Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 price objective on the stock. UBS Group reissued a “neutral” rating and set a $135.00 price objective on shares of Illumina in a research report on Friday, February 6th. Finally, Barclays increased their price objective on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Illumina has an average rating of “Hold” and an average price target of $138.38.

Insider Activity at Illumina

In other news, CAO Scott D. Ericksen sold 500 shares of the firm’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. This trade represents a 3.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president directly owned 15,056 shares in the company, valued at approximately $2,093,386.24. The trade was a 4.44% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,002,371 shares of company stock worth $155,472,900. 2.90% of the stock is owned by insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.